Clinical trial
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute…
NCT00112554 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00112554 |
|---|---|
| Title | Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia |
| Official title | A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Other |
| Interventions | cytarabine, laromustine, placebo |
| Enrollment | 420 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jun 3, 2005 |
| Last update posted | Nov 6, 2013 |
| Countries | Belgium, Canada, France, Germany, Greece, Netherlands, Poland, Serbia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: